Inogen Inc. Files Q3 2024 10-Q Report

TL;DR

Inogen's Q3 2024 10-Q is in. Check financials.

AI Summary

Inogen Inc. reported its Q3 2024 results, with the filing dated November 8, 2024. The company's fiscal year ends on December 31st. Key financial data and operational details for the period ending September 30, 2024, are presented in this 10-Q filing.

Why It Matters

This filing provides investors with the latest financial performance and operational updates for Inogen Inc., crucial for understanding the company's current health and future prospects.

Risk Assessment

Risk Level: medium — 10-Q filings often contain detailed financial information that can reveal risks and opportunities, requiring careful analysis.

Key Numbers

• Q3 2024 — Quarterly Period (Reporting period for the 10-Q filing.)
• 1231 — Fiscal Year End (Indicates the end of the company's financial year.)

Key Players & Entities

• Inogen Inc (company) — Filer
• 20240930 (date) — Reporting Period End Date
• 20241108 (date) — Filing Date
• 805-562-0500 (phone_number) — Business Phone
• Physio Assist Sas (company) — Subsidiary/Brand Mentioned

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value INGN The NASDAQ Stock Mar
• $0 — 8,413 shares of common stock, par value $0.001, outstanding. TABLE OF CONTENTS

Filing Documents

• ingn-20240930.htm (10-Q) — 2843KB
• ingn-ex31_1.htm (EX-31.1) — 16KB
• ingn-ex31_2.htm (EX-31.2) — 17KB
• ingn-ex32_1.htm (EX-32.1) — 7KB
• ingn-ex32_2.htm (EX-32.2) — 8KB
• 0000950170-24-124115.txt ( ) — 11191KB
• ingn-20240930.xsd (EX-101.SCH) — 1440KB
• ingn-20240930_htm.xml (XML) — 2255KB

– Financial Information

Part I – Financial Information Page Item 1.

Financial Statements

Financial Statements 3 Consolidated Balance Sheets (unaudited) as of September 30, 2024 and December 31, 2023 3 Consolidated Statements of Comprehensive Loss (unaudited) for the Three and Nine Months Ended September 30, 2024 and September 30, 2023 4 Consolidated Statements of Stockholders' Equity (unaudited) for the Three and Nine Months Ended September 30, 2024 and September 30, 2023 5 Consolidated Statements of Cash Flows (unaudited) for the Nine Months Ended September 30, 2024 and September 30, 2023 6 Condensed Notes to the Consolidated Financial Statements (unaudited) 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 39 Item 4.

Controls and Procedures

Controls and Procedures 40

– Other Information

Part II – Other Information Item 1.

Legal Proceedings

Legal Proceedings 41 Item 1A.

Risk Factors

Risk Factors 41 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 41 Item 3. Defaults Upon Senior Securities 41 Item 4. Mine Safety Disclosures 41 Item 5. Other Information 41 Item 6. Exhibits 42

SIGNATURES

SIGNATURES 43 2 INOGEN, INC.

– FINANC IAL INFORMATION

PART I – FINANC IAL INFORMATION

Financ ial Statements

Item 1. Financ ial Statements Inogen, Inc. Consol idated Balance Sheets (unaudited) (amounts in thousands, except share and per share amounts) September 30, 2024 December 31, 2023 Assets Current assets Cash and cash equivalents $ 105,690 $ 125,492 Marketable securities 14,973 2,979 Restricted cash 3,591 — Accounts receivable, net 34,233 42,241 Inventories, net 23,320 21,840 Income tax receivable 964 669 Prepaid expenses and other current assets 9,783 13,846 Total current assets 192,554 207,067 Property and equipment, net 46,598 50,316 Goodwill 10,170 10,057 Intangible assets, net 33,762 34,591 Operating lease right-of-use asset 19,017 20,338 Other assets 4,071 3,825 Total assets $ 306,172 $ 326,194 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued expenses $ 27,028 $ 30,142 Accrued payroll 14,285 11,066 Warranty reserve - current 9,492 9,628 Operating lease liability - current 2,777 3,653 Earnout liability 11,830 10,000 Deferred revenue - current 6,984 7,980 Income tax payable — 27 Total current liabilities 72,396 72,496 Long-term liabilities Warranty reserve - noncurrent 16,183 13,850 Operating lease liability - noncurrent 17,370 18,270 Deferred revenue - noncurrent 6,435 8,227 Deferred tax liability 8,384 8,539 Total liabilities 120,768 121,382 Commitments and contingencies (Note 10) Stockholders' equity Common stock, $ 0.001 par value per share; 200,000,000 authorized; 23,817,704 and 23,324,750 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 24 23 Additional paid-in capital 326,741 320,513 Accumulated deficit ( 143,080 ) ( 116,949 ) Accumulated other comprehensive income 1,719 1,225 Total stockholders' equity 185,404 204,812 Total liabilities and stockh

View Full Filing

View this 10-Q filing on SEC EDGAR